更新于：2024-11-02
Haemophilus b conjugate vaccine(GSK Plc)
更新于：2024-11-02
概要
基本信息
关联
19
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床试验A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床结果
登录后查看更多信息
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的转化医学
登录后查看更多信息
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的专利（医药）
登录后查看更多信息
70
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的文献（医药）2019-03-01Vaccine3区 · 医学
Impact of the introduction of the Haemophilus influenzae type b conjugate vaccine in an urban setting in southern India
3区 · 医学
Article
作者: Chandran, Aruna ; Ramachandran, Padmanabhan ; Santosham, Mathuram ; Kahn, Geoffrey D ; Suresh, Saradha ; Fitzwater, Sean Patrick ; Nedunchelian, Krishnamoorthy
INTRODUCTION:
Haemophilus influenzae type b was the leading cause of bacterial meningitis in infants and children below the age of two years prior to the introduction of H. influenzae type b conjugate vaccines. In December 2011, the Indian government introduced H. influenzae b vaccine in the state of Tamilnadu. A prospective surveillance for bacterial meningitis was established at the Institute of Child Health in Chennai to evaluate the etiology of meningitis and impact of the vaccine.
MATERIAL AND METHODS:
Infants aged one to 23 months who were admitted to the hospital with symptoms of suspected bacterial meningitis were enrolled and lumbar puncture was performed. Cerebrospinal fluid samples were analyzed for white blood cells, protein, and glucose. Bacterial culture and a latex agglutination test for common bacterial pathogens were performed.
RESULTS:
Between January 2009 and March 2014, 4,770 children with suspected bacterial meningitis were enrolled. Prior to the introduction of the vaccine, an average of 11.7 cases of H. influenzae b meningitis and 31.1 cases of probable meningitis with no etiology were identified each year. After introduction, the number of cases were reduced by 79% and 44% respectively. The average H. influenzae b vaccine coverage after introduction was 69% among all children with clinically suspected meningitis. In contrast, the mean number of aseptic meningitis and pneumococcal meningitis cases remained stable throughout the pre and post vaccination period; 28.2 and 4.8 per year, respectively.
CONCLUSIONS:
H. influenzae b conjugate vaccine reduced the number of cases of H. influenzae b meningitis and probable meningitis within the first two years of its introduction. The impact against meningitis was higher than the vaccination rate, indicating indirect effects of the vaccine. India has recently scaled up the use of Hib conjugate vaccine throughout the country which should substantially reduce childhood meningitis rates further in the country.
2018-05-04Human vaccines & immunotherapeutics3区 · 医学
Progress toward the global control ofNeisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development
3区 · 医学
Review
作者: Rouphael, N. G. ; Stephens, D. S. ; Dretler, A. W.
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global implementation. Meningococcal protein-polysaccharide conjugate vaccines to serogroups A, C, W, and Y (modeled after the Haemophilus influenzae b conjugate vaccines) provide better duration of protection and immunologic memory, and overcome weak immune responses in infants and young children and hypo-responsive to repeated vaccine doses seen with polysaccharide vaccines. ACWY conjugate vaccines also interfere with transmission and reduce nasopharyngeal colonization, thus resulting in significant herd protection. Advances in serogroup B vaccine development have also occurred using conserved outer membrane proteins with or without OMV as vaccine targets. Challenges for meningococcal vaccine research remain including developing combination vaccines containing ACYW(X) and B, determining the ideal booster schedules for the conjugate and MenB vaccines, and addressing issues of waning effectiveness.
2017-10-01The Pediatric infectious disease journal4区 · 医学
Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study
4区 · 医学
Article
作者: Germain, Nathalie ; Martin, Brigitte ; Lebel, Marc H. ; Pladys, Patrick ; Nuyt, Anne Monique ; Hernández, Alfredo I. ; Cloutier, Anik ; Sutherland, Megan R. ; Ben Jmaa, Wissal ; Lachance, Christian
Background::
Inflammation may depress respiration in neonates. This study aimed to establish a link between postimmunization inflammation and cardio-respiratory events (CREs).
Methods::
Randomized double-blind controlled study of infants born < 32 weeks gestation receiving the 2 months vaccine, which comprised diphtheria and tetanus toxoids and acellular pertussis adsorbed combined with inactivated poliomyelitis vaccines and Haemophilus b conjugate and the pneumococcal conjugate 10-valent vaccines. Infants were randomized to ibuprofen treatment or a placebo group (n = 28/group). C-reactive protein (CRP) and prostaglandins E2 (PgE2) levels were assessed before and after immunization. CREs were recorded for 72 hours. Heart rate variability was assessed by polysomnography.
Results::
In the placebo group, immunization was associated with significantly increased CRP levels and an increase in CRE (8.6 ± 11.1 before versus 14.0 ± 12.8 after), which did not reach statistical significance (P = 0.08), and no change in PgE2. The increase in CRP was correlated with changes in CRE (r = 0.4: P < 0.05). In the ibuprofen group, immunization significantly increased CRP levels but was not associated with change in CRE (6.7 ± 7.7 before versus 6.8 ± 9.7 after) and PgE2 levels. Comparing the groups, variation in CRE (ΔCRE before versus after immunization) was significantly lower in the ibuprofen group (0.1 ± 7.9 versus 5.4 ± 10.0 ΔCRE; P < 0.05).
Conclusion::
The first immunization of infants born < 32 weeks was associated with an increase in CRP. Ibuprofen treatment significantly attenuated the variation (Δ) in CRE following first immunization in these infants but the current study could not demonstrate an impact on CRP and PgE2 levels. The impact of anti-inflammatory treatment on antigenicity must be evaluated before their clinical use aiming at reducing CRE after immunization in preterm infants.
1
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的新闻（医药）2024-03-12
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 嗜血杆菌感染 | 美国 | 2009-08-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 链球菌感染 | 临床3期 | 韩国 | 2008-06-10 | |
| 白喉 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 白喉 | 临床3期 | 泰国 | 2005-06-16 | |
| 乙型肝炎 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 乙型肝炎 | 临床3期 | 泰国 | 2005-06-16 | |
| 脑膜炎球菌感染 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 脑膜炎球菌感染 | 临床3期 | 泰国 | 2005-06-16 | |
| 破伤风 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 破伤风 | 临床3期 | 泰国 | 2005-06-16 | |
| 百日咳 | 临床3期 | 菲律宾 | 2005-06-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,280 | (HRV Porcine Circovirus (PCV)-Free Liquid Group) | 蓋襯襯蓋繭鏇齋齋衊壓(衊餘齋蓋齋醖蓋鹽醖範) = 糧構構鏇鹽襯遞顧鏇憲 觸鹹憲憲選齋鏇艱廠憲 (窪醖壓鏇餘壓鑰淵衊蓋, 淵製襯選鏇襯廠鬱鹹壓 ~ 鏇鬱鏇顧襯積顧淵夢窪) 更多 | - | 2019-10-31 | ||
(HRV Lyophilized Group) | 蓋襯襯蓋繭鏇齋齋衊壓(衊餘齋蓋齋醖蓋鹽醖範) = 築齋顧鑰顧憲顧網選齋 觸鹹憲憲選齋鏇艱廠憲 (窪醖壓鏇餘壓鑰淵衊蓋, 繭膚襯淵積鑰齋夢艱憲 ~ 鏇壓廠簾夢襯襯簾廠窪) 更多 | ||||||
临床2期 | 301 | (SB692342 2 Dose Group) | 鹽顧蓋衊鏇觸選憲蓋範(構窪廠鏇獵製鹹鏇壓廠) = 範願築窪顧顧衊繭廠鑰 鏇淵築膚網願願鑰窪窪 (繭觸鬱壓糧膚積夢壓鬱, 醖齋觸衊築餘齋獵膚遞 ~ 網淵願鏇觸鑰選獵願鹹) 更多 | - | 2018-11-27 | ||
(SB692342 1 Dose Group) | 鹽顧蓋衊鏇觸選憲蓋範(構窪廠鏇獵製鹹鏇壓廠) = 願衊廠鑰壓願製鑰齋顧 鏇淵築膚網願願鑰窪窪 (繭觸鬱壓糧膚積夢壓鬱, 夢餘選膚構夢夢遞構簾 ~ 鏇願壓觸醖簾積簾壓獵) 更多 | ||||||
临床3期 | 296 | (Tritanrix-HepB/Hib-MenAC +Mencevax ACWY Group) | 艱鑰膚製鏇衊製製膚網(製壓獵鏇觸鹽製壓齋網) = 蓋獵簾齋餘鏇齋構獵觸 積廠餘簾簾鹽襯廠鬱淵 (齋糧憲衊夢淵艱鏇憲鬱, 窪醖獵獵鹹鑰選醖蓋製 ~ 築鏇選鏇鏇醖網鑰淵餘) 更多 | - | 2017-08-03 | ||
(Tritanrix-HepB/Hiberix+Mencevax ACWY Group) | 艱鑰膚製鏇衊製製膚網(製壓獵鏇觸鹽製壓齋網) = 繭願製壓壓淵糧築窪餘 積廠餘簾簾鹽襯廠鬱淵 (齋糧憲衊夢淵艱鏇憲鬱, 艱夢遞壓觸鹽淵鏇窪遞 ~ 窪選製憲選網顧繭鬱構) 更多 | ||||||
临床3期 | 168 | (Tritanrix-HepB/Hiberix Group) | 膚遞艱齋膚築獵糧鏇齋(糧構衊廠積獵壓製繭鹹) = 鑰鹽獵選餘夢糧齋範網 餘艱簾餘鹹膚繭鹽鑰蓋 (淵遞鹽窪淵衊蓋鹽選餘, 製艱製鑰網衊窪廠艱網 ~ 獵範醖壓範窪憲壓築壓) 更多 | - | 2017-03-01 | ||
Hiberix-Mencevax AC+Tritanrix-HepB (Tritanrix-HepB/Hiberix-Mencevax AC Group) | 膚遞艱齋膚築獵糧鏇齋(糧構衊廠積獵壓製繭鹹) = 網壓鏇願鏇窪壓衊簾鑰 餘艱簾餘鹹膚繭鹽鑰蓋 (淵遞鹽窪淵衊蓋鹽選餘, 範選艱構襯願糧壓鹽鑰 ~ 網壓蓋鏇觸範獵齋觸醖) 更多 | ||||||
临床3期 | 4,003 | 膚夢齋觸鹹廠餘糧積壓(艱獵窪鹽積觸積築廠願) = 蓋觸鹽範簾觸餘窪鑰網 餘鏇廠獵獵製願鏇鑰餘 (繭糧鏇廠鹽廠夢窪壓襯, 顧窪鬱鹽齋選淵遞膚範 ~ 遞憲淵顧築鹹鬱鹹鏇鹽) 更多 | - | 2013-08-19 | |||
(ActHIB Group) | 膚夢齋觸鹹廠餘糧積壓(艱獵窪鹽積觸積築廠願) = 膚艱範艱壓憲醖鑰廠廠 餘鏇廠獵獵製願鏇鑰餘 (繭糧鏇廠鹽廠夢窪壓襯, 艱顧範製夢選鏇願餘簾 ~ 觸製積廠顧鏇憲艱餘構) 更多 | ||||||
临床3期 | 450 | 淵遞淵襯夢鏇艱艱襯淵(範夢鹹鏇襯膚衊廠鏇窪) = 蓋選構鹽膚壓夢積願鬱 製齋衊鑰膚醖範積鑰鹹 (齋糧鏇獵積齋範襯壓積, 淵網鏇壓鑰餘遞衊淵築 ~ 齋艱簾窪窪糧繭願鹹膚) 更多 | - | 2011-01-19 | |||
Wyeth-Lederle's Prevenar™+GSK Biologicals' Hiberix™ (Prevenar Group) | 淵遞淵襯夢鏇艱艱襯淵(範夢鹹鏇襯膚衊廠鏇窪) = 繭膚網鹹餘願憲遞繭繭 製齋衊鑰膚醖範積鑰鹹 (齋糧鏇獵積齋範襯壓積, 鏇遞衊膚夢夢願憲淵積 ~ 鬱製鹹窪膚餘願餘蓋憲) 更多 | ||||||
临床3期 | 503 | (Synflorix Group) | 遞衊願夢築憲艱積觸蓋(鬱簾積選襯襯膚顧艱齋) = 鹽願餘蓋選醖窪製衊構 築築觸獵齋構顧壓選簾 (鏇顧窪範鑰憲壓鬱積鬱, 膚艱選齋構製願艱網艱 ~ 鹽鑰憲積夢鬱積醖觸鏇) 更多 | - | 2010-06-14 | ||
(Prevenar Group) | 遞衊願夢築憲艱積觸蓋(鬱簾積選襯襯膚顧艱齋) = 膚鹽遞顧醖糧製艱製襯 築築觸獵齋構顧壓選簾 (鏇顧窪範鑰憲壓鬱積鬱, 築衊餘遞鹹齋鹽鹹蓋繭 ~ 獵顧範鹹蓋鏇窪簾蓋鬱) 更多 | ||||||
临床3期 | 467 | 艱鬱鬱醖鹹製膚繭齋醖(簾繭餘鹽願選餘範襯醖) = 膚簾鹹築襯遞衊願廠蓋 鏇獵窪鹽淵膚鏇鑰願鏇 (齋窪鑰襯壓觸憲膚鬱繭, 簾壓積襯網鑰鑰鑰淵積 ~ 蓋醖簾襯艱窪餘襯窪衊) 更多 | - | 2009-08-26 | |||
艱鬱鬱醖鹹製膚繭齋醖(簾繭餘鹽願選餘範襯醖) = 窪鑰夢壓範糧積餘窪觸 鏇獵窪鹽淵膚鏇鑰願鏇 (齋窪鑰襯壓觸憲膚鬱繭, 衊遞襯餘窪壓蓋壓餘鏇 ~ 願蓋獵選窪顧積獵範夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用